To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive
a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles.
Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive
evaluation and ratings from patients.
Dr. Edelman collaborates with our clinical, scientific, and administrative leadership to grow robust therapeutic, clinical research, and translational research programs in hematology and medical oncology while leading the department in evaluating emerging national trends in the delivery of care to cancer patients. Dr. Edelman is the inaugural Chair of the Department of Lewis Katz School of Medicine. In addition, Dr. Edelman is Associate Cancer Center Director for Clinical Research Integration, responsible for developing the clinical research program throughout the Temple University Health System.
A nationally recognized expert in the treatment and research of lung cancer, Dr. Edelman developed one of the most commonly used regimens for treating advanced lung cancer and has focused on the development of new agents and biomarkers to personalize lung cancer therapy. He has a particular interest in approaches that integrate surgery, radiation, and chemotherapy in the management of lung cancer patients. His research has been supported by grants and contracts from the NCI, DOD and industry.
Dr. Edelman serves on the Thoracic Malignancies Steering Committee of the National Cancer Institute’s Scientific Review Group. He has been an active member of the National Clinical Trials Network for over 35 years and is the Medical Oncology Co-chair for the Lung Cancer Committee of the Radiation Therapy Oncology Group (RTOG, NRG). He is an active member and past chair of the Career Development and Ethics Committee and currently a member of the Communications Committee of the International Association for the Study of Lung Cancer (IASLC). He is a member of the Small Cell committee of the NCCN and the Executive Committee of the American Radium Society.
Dr. Edelman has published more than 325 scientific articles, abstracts, and book chapters. In addition, he has served on the editorial boards or as an ad-hoc reviewer of numerous academic journals and currently serves as Deputy Editor of the journal Lung Cancer.
Postdoctoral Scholar, University of California, San Diego, CA 1990
Fellowship, Hematology/Oncology, Naval Hospital, San Diego, CA 1990
Residency, Internal Medicine, Naval Hospital, San Diego, CA, 1986
Internship, Internal Medicine, Naval Hospital, San Diego, CA, 1983
MD, The Albany Medical College, Albany, NY, 1982
BS, Biology (cum laude), Rensselaer Polytechnic Institute, Troy, NY, 1982
American Board of Internal Medicine, subspecialty certificate in Hematology 1990
American Board of Internal Medicine, subspecialty in Medical Oncology 1989
American Board of Internal Medicine 1986
National Board of Medical Examiners 1983
American Society for Clinical Oncology
European Society of Medical Oncology
International Association for the Study of Lung Cancer
Thoracic Malignancies Steering Committee of the National Cancer Institute
Lung Cancer Committee of the Radiation Therapy Oncology Group (RTOG, NRG): Medical Oncology Co-Chair
Honors & Awards
Philadelphia Magazine Top Doctors, 2018-22
America's Top Doctors®, 2017
Fellow, American College of Physicians 2011
Teaching Award, Department of Medicine, University of Maryland 2010
Award from Undersecretary of VA for Health Affairs 1998
Thoracic oncology malignancies; lung metastases
The following ratings and reviews are based on verified feedback collected from independently administered
patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions.
Patient identities are withheld to ensure confidentiality and privacy.
Learn more about our Patient Experience Ratings.
“We’re dealing with lung cancer and our lung cancer patients may be more at risk for severe disease due to COVID-19. A lot of the management we do puts them at greater risk after that,” said Sameera Kumar, MD, one of the authors on the paper and an assistant professor in the Department of Radiation Oncology.